Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis [2]

Clinical and Experimental Rheumatology

Volumn 24, Issue 6, 2006, Pages 723-

  Boulman, Nina ^a   Rozenbaum, M ^a   Slobodin, G ^a   Rosner, I ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMIKACIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CIPROFLOXACIN; GAMMA GLUTAMYLTRANSFERASE; INFLIXIMAB; LIVER ENZYME; METHOTREXATE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DIAGNOSTIC ERROR; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOMATOUS HEPATITIS; HUMAN; HUMAN TISSUE; LETTER; LIVER BIOPSY; MYCOBACTERIOSIS; MYCOBACTERIUM FORTUITUM; PHLEBITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TUBERCULIN TEST;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS;

EID: 33846426816     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. CRISCIONE LG, St CLAIR EW: Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14: 204-11.
2. STRAND V, KEYSTONE E: Anticytokine therapies in rheumatoid arthritis. 2004, www.uptodate.com
3. DINARELLO CA: Anti-cytokine therapeutics and infections. Vaccine 2003; 21 (Suppl. 2): S24-34.
4. GARDAM MA, KEYSTONE EC, MENZIES R et al.: Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
5. GRIFFTH DE, WALLACE RJ: Clinical manifestations of nontuberculosus mycobacterial infections in HIV-negative patients. 2004, www.uptodate.com
6. INGRAM CW, TANNER DC, DURACK DT, KERNODLE GW Jr, COREY GR: Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis 1993; 16: 463-71.
7. BRANNAN DP, DUBOIS RE, RAMIREZ MJ, RAVRY MJ, HARRISON EO: Cefoxin therapy for Mycobacterium fortuitum bacteremia with associated granulematous hepatitis. South Med J 1984; 77: 381-4.
8. BAHRMAND AR, MADANI H, SAMAR G et al.: Detection and identification of non-tuberculous mycobacterial infection in 6,427 tuberculosis suspected patients. Scand J Infect Dis 1996; 28: 275-8.
9. LEIBOWITZ MR, CURRIER JS: Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients.2004, www.uptodate.com
10. IMPERATO AK, BINGHAM CO 3rd, ABRAMSON SB: Overview of benefits/risk of biological agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S108-14.